Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Eli Lilly Will Start Selling Cialis Impotency Pill in Japan (Japan)

This article was originally published in PharmAsia News

Executive Summary

Eli Lilly is now selling its Cialis impotency pill in Japan, and has increased its sales force in Japan by 100 to 900 in April. The drug firm's goal is to move from its current spot of 26th to become one of the 20 largest drugmakers in Japan by 2010. "Cialis plays an important role not just in its total sales, but it's also important in terms of capability building," says Newton Crenshaw, president of Eli Lilly's Japanese unit. "We are working hard to expand our efforts to the GP and small-clinic market." Drug sales increased in 2005 the most in 14 years, spurred by the nation's aging population, according to a PricewaterhouseCoopers report. Lilly estimates about 15 billion yen worth of treatments for erectile dysfunction are imported directly by Japanese users each year. Lilly's Japan unit increased revenue by 7 percent to 82.2 billion yen in the year ended Dec. 31, driven by an 11 percent jump in sales of the Zyprexa schizophrenia medicine. (Click here for more - May Require Free Registration
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC066520

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel